NewLimit is a South San Francisco-based biotechnology company developing epigenetic reprogramming medicines to extend human healthspan by restoring youthful function in aging cells. Its lead program uses mRNA delivered via lipid nanoparticles to rejuvenate aged liver cells (hepatocytes), targeting alcohol-related liver disease as an initial indication with plans to expand broadly. The company combines functional genomics, pooled perturbation screening, and machine learning to identify transcription factor combinations that reverse cellular aging at scale.